Business Practice

When it comes to delivering medicines to patients in need, choosing the right packaging partner can make all the difference.

After a madcap back and forth between leading and dissenting Democrats, Biden’s drug pricing reform plans have reached a compromised final form.

The FDA has approved just three biosimilars in 2021 – but the approvals could shake up the field as discussions around interchangeability intensify.

Biotech companies need good patient samples, but hospitals are not always obliging...

Sai Rangarao has worked for some of the biggest names in pharma. Here’s his advice to digital marketers in the field.

The efforts of CDMOs have been absolutely crucial in the pandemic response. We ask five CDMO gurus how they reacted to COVID-19.

Part 2 of our roundtable discussion with CDMOs covers outsourcing preferences, the demand for mRNA, and more.

In this video interview, Mike Rea explains why each drug needs its own launch strategy.

The way the pharma industry has traditionally handled clinical trials does not make participation easy.

We speak with the authors of two studies into extreme increases in US drug pricing, and attempts by lawmakers to bring the price-jackers into line.